Syringe Driver Survey Database migration to MedicinesComplete - January 2023

Syringe Driver Survey Database has moved to MedicinesComplete and is no longer available on palliativedrugs.com.

It has been renamed to PCF’s Syringe Driver Database and is now accessed through Drug Compatibility Checker.

Drug Compatibility Checker, through MedicinesComplete is a new tool providing essential compatibility knowledge to support the administration of injectable drugs combining published data and clinical practice reports.

Find out more about Drug Compatibility Checker:https://about.medicinescomplete.com/publication/drug-compatibility-checker/

If you have a subscription to Palliative Care Formulary through MedicinesComplete, you will have access to PCF’s Syringe Driver Database through Drug Compatibility Checker, at no charge through 2023. 

To contribute to PCF’s Syringe Driver Database please continue to submit a clinical practice report using palliativedrugs.com here: https://www.palliativedrugs.com/syringe-driver-database.html

To learn more about a subscription to the Palliative Care Formulary through MedicinesComplete, please contact us here: https://info.medicinescomplete.com/sales

If you have any questions regarding access to PCF’s Syringe Driver Database or would like to renew your subscription to Palliative Care Formulary, please contact pharmpress-support@rpharms.com.

---

Use of dexamethasone formulations in palliative care: a palliativedrugs.com response to recent changes

18th December 2014

Following the recent changes in the formulation of one of the dexamethasone injections in the UK (see our news item 21 October 2014), we have put together a palliativedrugs.com summary in order to clarify the situation on the use of dexamethasone formulations in adults in palliative care. This can be downloaded from the link below. The on-line PCF systemic corticosteroids monograph will be updated shortly to reflect this guidance.

In addition, there is now a manufacturer's supply problem with the Hospira brand of dexamethasone base 3.3mg/mL, 1mL ampoules, which is not expected to be resolved before January 2015.

click here to view